Skip to main content

When do the Eylea and Eylea HD patents expire?

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 1, 2023.

Official answer


Eylea and Eylea HD patents are due to run out from 2023 to 2039; however, these should not be taken as definite dates as there are many ways drug companies can extend their patents, for example, by changing the formulation of their product. For example, the original patent term for Regeneron was extended from May 23, 2020, to June 16, 2023.

The current patent expiry dates for Eylea are as follows:

  • Composition of matter (for a composition of at least 2 ingredients): June 16, 2023
  • Formulation patents (4 of these): June 14, 2027 (for 2); June 21, 2027; March 22, 2026
  • Methods of treatment patents (3 of these): March 22, 2026, and January 11, 2032 (for 2)
  • Method of manufacturing: March 22, 2026
  • Composition of matter (supplementary protection certificate): May 23, 2025.

At least 5 Eylea HD patents are the same as Eylea patents, typically extending the patent expiry date.

  • One new patent, US11103552B2 which relates to high concentration VEGF receptor fusion protein containing formulations, has a patent expiry date of 15 May 2039.

Because pharmaceutical companies make about 80% of their overall revenue while their drug is on patent, they will often try many legal techniques to extend their patents for as long as they can. Once patents fully expire, generic companies can copy the formulation, saving the cost of years of research, and undercutting the original company’s prices significantly.


Read next

Related medical questions

Drug information

Related support groups